Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

Open access

Abstract

Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2) with moderate-level (“standard”) support for spiritual-practice (LD-SS); (2) high-dose (20 and 30 mg/70 kg on sessions 1 and 2, respectively) with standard support (HD-SS); and (3) high-dose (20 and 30 mg/70kg on sessions 1 and 2, respectively) with high support for spiritual practice (HD-HS). Psilocybin was administered double-blind and instructions to participants/staff minimized expectancy confounds. Psilocybin was administered 1 and 2 months after spiritual-practice initiation. Outcomes at 6 months included rates of spiritual practice and persisting effects of psilocybin. Compared with low-dose, high-dose psilocybin produced greater acute and persisting effects. At 6 months, compared with LD-SS, both high-dose groups showed large significant positive changes on longitudinal measures of interpersonal closeness, gratitude, life meaning/purpose, forgiveness, death transcendence, daily spiritual experiences, religious faith and coping, and community observer ratings. Determinants of enduring effects were psilocybin-occasioned mystical-type experience and rates of meditation/spiritual practices. Psilocybin can occasion enduring trait-level increases in prosocial attitudes/behaviors and in healthy psychological functioning. Trial Registration ClinicalTrials.gov Identifier NCT00802282

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881117731279

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Within-session time-course of guide ratings of overall psilocybin effect during the sessions. Data points are means; brackets show ± 1 SEM (n=25); time 0=before capsule administration). The High-Dose High-Support and the High-Dose Standard-Support groups were significantly different from the Low-Dose Standard-Support group at all post-capsule time-points. The two high-dose groups were not significantly different at any time-points except for 60 and 90 minutes in Session 2.
Figure 1. Within-session time-course of guide ratings of overall psilocybin effect during the sessions. Data points are means; brackets show ± 1 SEM (n=25); time 0=before capsule administration). The High-Dose High-Support and the High-Dose Standard-Support groups were significantly different from the Low-Dose Standard-Support group at all post-capsule time-points. The two high-dose groups were not significantly different at any time-points except for 60 and 90 minutes in Session 2.CC BY-NC · PubMed Central
Figure 2. Guide ratings of volunteer behavior and mood assessed throughout the psilocybin sessions (Illustrative results from Table 2). Data are means of the peak response in each of the two psilocybin sessions in each participant. Bars show group means; brackets show 1 SEM; * indicates a significant difference from Low-Dose Standard-Support (Planned comparisons, p<.05); there were no significant differences between the High-Dose High-Support and High-Dose Standard-Support groups.
Figure 2. Guide ratings of volunteer behavior and mood assessed throughout the psilocybin sessions (Illustrative results from Table 2). Data are means of the peak response in each of the two psilocybin sessions in each participant. Bars show group means; brackets show 1 SEM; * indicates a significant difference from Low-Dose Standard-Support (Planned comparisons, p<.05); there were no significant differences between the High-Dose High-Support and High-Dose Standard-Support groups.CC BY-NC · PubMed Central
Figure 3. Participant ratings on mystical experience questionnaires completed 7 hours after psilocybin administration (Illustrative results from Table 3). Data for the Mystical Experience Questionnaire (MEQ30) are percentages of the maximum possible score; data for the Mysticism Scale are total scores. Bars show group means; brackets show 1 SEM; * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support and the High-Dose Standard-Support groups (Planned comparisons, p<0.05).
Figure 3. Participant ratings on mystical experience questionnaires completed 7 hours after psilocybin administration (Illustrative results from Table 3). Data for the Mystical Experience Questionnaire (MEQ30) are percentages of the maximum possible score; data for the Mysticism Scale are total scores. Bars show group means; brackets show 1 SEM; * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support and the High-Dose Standard-Support groups (Planned comparisons, p<0.05).CC BY-NC · PubMed Central
Figure 4. Spiritual practices at 6 months (from Table 4). Data, which were obtained at the 6-month follow-up, show retrospective ratings for the past 4 months. Bars displaying rate data show means; brackets show 1 SEM (n=25). Meditation rate data are minutes per day for all days. Bars displaying proportion data show the percentage of the group (n=25) reporting the practice during the indicated time interval. * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05).
Figure 4. Spiritual practices at 6 months (from Table 4). Data, which were obtained at the 6-month follow-up, show retrospective ratings for the past 4 months. Bars displaying rate data show means; brackets show 1 SEM (n=25). Meditation rate data are minutes per day for all days. Bars displaying proportion data show the percentage of the group (n=25) reporting the practice during the indicated time interval. * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05).CC BY-NC · PubMed Central
Figure 5. Participant ratings of effects attributed to psilocybin session experiences at the 6-month follow-up (Illustrative results from Table 5). Data on altruistic/social effects, behavior changes, and spirituality are expressed as percentage of maximum possible score (bars show means, brackets show 1 SEM, n=25). Data for the questions about spiritual significance and change in well-being or life satisfaction are either raw scores (bars show means, brackets show 1 SEM, n=25) or percentages of the group (n=25). * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05).
Figure 5. Participant ratings of effects attributed to psilocybin session experiences at the 6-month follow-up (Illustrative results from Table 5). Data on altruistic/social effects, behavior changes, and spirituality are expressed as percentage of maximum possible score (bars show means, brackets show 1 SEM, n=25). Data for the questions about spiritual significance and change in well-being or life satisfaction are either raw scores (bars show means, brackets show 1 SEM, n=25) or percentages of the group (n=25). * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05).CC BY-NC · PubMed Central
Figure 6. Longitudinal measures assessed at the 6-month follow-up (Illustrative results from Table 6). Bars show means; brackets show 1 SEM (n=25); ★ indicates a significant difference between baseline and 6 months; * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05). For comparison, dotted lines show mean scores from previous studies for each measure: Mysticism Scale (college students, Hood et al., 2001; Ralph W. Hood Jr, personal communication); Faith Maturity Scale (university students, Loma Linda University, 2007), Daily Spiritual Experience Scale (general population survey data, Underwood, 2006); Gratitude Questionnaire-6 (adults, McCullough et al., 2002); Life Meaning (college and community sample, Reker, 2007); Trait Forgiveness Scale (college students, Berry et al., 2005); Forgiveness Benevolence Motivation (college students, Tsang et al., 2006); Sanctification of Strivings (adults, Mahoney et al., 2005).
Figure 6. Longitudinal measures assessed at the 6-month follow-up (Illustrative results from Table 6). Bars show means; brackets show 1 SEM (n=25); ★ indicates a significant difference between baseline and 6 months; * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05). For comparison, dotted lines show mean scores from previous studies for each measure: Mysticism Scale (college students, Hood et al., 2001; Ralph W. Hood Jr, personal communication); Faith Maturity Scale (university students, Loma Linda University, 2007), Daily Spiritual Experience Scale (general population survey data, Underwood, 2006); Gratitude Questionnaire-6 (adults, McCullough et al., 2002); Life Meaning (college and community sample, Reker, 2007); Trait Forgiveness Scale (college students, Berry et al., 2005); Forgiveness Benevolence Motivation (college students, Tsang et al., 2006); Sanctification of Strivings (adults, Mahoney et al., 2005).CC BY-NC · PubMed Central
Figure 7. Two observer-rated measures of participant attitudes and behavior assessed at the 6-month follow-up (from Table 6). Bars show means; brackets show 1 SEM (n=25); for both measures, * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05). For the ASPIRES, which was assessed both at baseline and the 6-month follow-up, ★ indicates a significant difference between baseline and 6 months (Planned comparisons, p<0.05). Also for the ASPIRES, dotted line shows mean norm score (Piedmont, 2010).
Figure 7. Two observer-rated measures of participant attitudes and behavior assessed at the 6-month follow-up (from Table 6). Bars show means; brackets show 1 SEM (n=25); for both measures, * indicates a significant difference from the Low-Dose Standard-Support group; + indicates a significant difference between the High-Dose High-Support group and the High-Dose Standard-Support group (Planned comparisons, p<0.05). For the ASPIRES, which was assessed both at baseline and the 6-month follow-up, ★ indicates a significant difference between baseline and 6 months (Planned comparisons, p<0.05). Also for the ASPIRES, dotted line shows mean norm score (Piedmont, 2010).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 14

  1. Costa PT, 1992, Revised NEO Personality Inventory (NEO-PI-R) and NEO Five-Factor Inventory (NEO-FFI) (Professional manual)
  2. Darling DC, 2004, Teonanacatl: Sacred Mushroom of Visions, 135
  3. Doblin R, 1991, J Transpersonal Psy, 23, 1
  4. Easwaran E, 1991, Meditation: A Simple Eight-Point Program for Translating Spiritual Ideals into Daily Life
  5. The Fetzer Institute, 1999, Multidimensional Measurement of Religiousness/Spirituality for use in Health Research: A Report of the Fetzer Institute/National Institute on Aging Working Group, 85
  6. Pahnke W, 1963, Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness
  7. Pargament KI, 1999, Multidimensional Measurement of Religiousness/Spirituality for Use in Health Research: A Report of the Fetzer Institute/National Institute on Aging Working Group, 43
  8. Passie T, 2004, Teonanacatl: Sacred Mushroom of Visions, 109
  9. Passie T, 2007, Psychedelic Medicine, 1, 45
  10. Piedmont RL, 2010, ASPIRES: Assessment of Spirituality and Religious Sentiments (Technical Manual)
  11. Reker GT, 2007, The Life Attitude Profile-Revised (LAP-R) (Procedures Manual)
  12. Stevens J, 1987, Storming Heaven
  13. VandeCreek L, 1999, Measures of Religiousity, 442
  14. Weil GM, 1965, The Psychedelic Reader, 13

Cited by

See all 558

Metadata

Authors
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A.
Affiliations
  • Johns Hopkins University (US)
  • Council on Spiritual Practices, Occidental, USA
  • Center for Optimal Living, New York, USA
Corresponding author
Griffiths, Roland R
Venue
Journal of Psychopharmacology
Published
2017-10-11
Volume
32
Issue
1
Pages
49-69
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2762822955
Cited by
520
References
58
Citations by year
2026: 47 · 2025: 76 · 2024: 83 · 2023: 91 · 2022: 89 · 2021: 60 · 2020: 37 · 2019: 19 · 2018: 16 · 2017: 1
FWCI
24.76
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Fetzer Institute
  • National Institute on Drug Abuse (R01DA003889)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Health › Religion, Spirituality, and Psychology
  • Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
Keywords
psilocybin, meditation, spiritual practice, prosocial attitudes, prosocial behavior, well-being, gratitude, meaning of life, forgiveness, faith, coping, relationship closeness, dose-response relationship, psychedelic-assisted psychotherapy
MeSH terms
Adult, Aged, Attitude, Behavior, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Middle Aged, Mysticism, Psilocybin, Meditation, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. https://app.cochat.ai/papers/10.1177/0269881117731279
The paper
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117731279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.